Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD-1: durvalumab with TACE with or without bevacizumab in localized hepatocellular carcinoma
CTR20190594Phase 3Active
- Sponsor
- MedImmune
- Start
- Dec 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in hepatocellular carcinoma (HCC), sponsored by MedImmune. Started Dec 2020; status: active.
02
Drugs
durvalumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20190594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190594.